PDS Biotechnology News

Express News | PDS Biotech To Event To Discuss Positive, Updated Data From Phase 2 VERSATILE-002 Clinical Trial With Versamune HPV In Combination With KEYTRUDA In Recurrent Or Metastatic Head And Neck Cancer

Moomoo 24/7Apr 23 08:01 ET

PDS Biotechnology Corporation's (NASDAQ:PDSB) Market Cap Dropped US$1.5m Last Week; Individual Investors Who Hold 59% Were Hit as Were Institutions

Yahoo FinanceMar 30 08:35 ET

PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2023 Earnings Call Transcript

Yahoo FinanceMar 28 10:15 ET

Noble Financial Sticks to Its Buy Rating for PDS Biotechnology (PDSB)

TipRanksMar 28 08:25 ET

B. Riley Securities Adjusts PDS Biotechnology's Price Target to $11 From $14, Maintains Buy Rating

B. Riley Securities Adjusts PDS Biotechnology's Price Target to $11 From $14, Maintains Buy Rating.

MT NewswiresMar 28 07:57 ET

PDS Biotechnology: Strategic Shift to Triplet Therapy Promises Enhanced Clinical Success

TipRanksMar 28 07:25 ET

Q4 2023 PDS Biotechnology Corp Earnings Call

Yahoo FinanceMar 27 23:33 ET

Earnings Call Summary | PDS Biotechnology(PDSB.US) Q4 2023 Earnings Conference

The following is a summary of the PDS Biotechnology Corporation (PDSB) Q4 2023 Earnings Call Transcript:Financial Performance:PDS Biotechnology Corporation reported a net loss of approximately $42.9 m

moomoo AIMar 27 12:35 ET · Conference Call

PDS Biotechnology Is Maintained at Buy by HC Wainwright & Co.

PDS Biotechnology Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMar 27 10:39 ET

PDS Biotechnology: A Strong Buy on Strategic Focus and Promising HNSCC Trial Data

TipRanksMar 27 10:35 ET

HC Wainwright & Co. Maintains Buy on PDS Biotechnology, Maintains $21 Price Target

HC Wainwright & Co. analyst Joseph Pantginis maintains PDS Biotechnology with a Buy and maintains $21 price target.

Analyst UpgradesMar 27 10:28 ET

PDS Biotechnology Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/27/2024 459.25% HC Wainwright & Co. $21 → $21 Maintains Buy 11/15/2023 432.62% Oppenheimer $23 → $20 Ma

BenzingaMar 27 10:27 ET

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

GainersLixte Biotechnology (NASDAQ:LIXT) shares moved upwards by 67.2% to $3.77 during Wednesday's pre-market session. The market value of their outstanding shares is at $8.4 million. Nutriband (NASDA

BenzingaMar 27 09:05 ET

PDS Biotechnology GAAP EPS of -$1.39 Beats by $0.06

Seeking AlphaMar 27 07:31 ET

PDS Biotechnology 2023 Research and Development Expenses $27.8M >PDSB

PDS Biotechnology 2023 Research and Development Expenses $27.8M >PDSB

Dow JonesMar 27 07:31 ET

Press Release: PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results

PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results Unique mechanism of action of the combination of PDS01ADC and Versamune(R) results in 3-year survival of 75

Dow JonesMar 27 07:30 ET

PDS Biotechnology 2023 Loss/Shr $1.39 >PDSB

PDS Biotechnology 2023 Loss/Shr $1.39 >PDSB

Dow JonesMar 27 07:30 ET

Earnings Scheduled For March 27, 2024

Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million. • REE Automotive (NASDAQ:REE) is estimated to repor

BenzingaMar 27 05:02 ET

PDS Biotechnology FY 2023 Earnings Preview

Seeking AlphaMar 26 13:47 ET

Earnings Preview For PDS Biotechnology

PDS Biotechnology (NASDAQ:PDSB) is set to give its latest quarterly earnings report on Wednesday, 2024-03-27. Here's what investors need to know before the announcement.Analysts estimate that PDS Biot

BenzingaMar 26 12:01 ET